Drugs / Tumor Infiltrating Lymphocytes
Tumor Infiltrating Lymphocytes
also known as
Tumor Infiltrating Lymphocytes (TIL) · lifileucel · LN-145 · TIL · TILs · LN-144 · Tumor infiltrating lymphocyte · AMTAGVI · +2 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Clinical hold | US (FDA) | — | non-small cell lung carcinoma | 2024-03-04 | “FDA lifted a partial clinical hold placed on the registrational IOV-LUN-202 trial investigating LN-145 TIL cell therapy in non-small cell lung cancer” iovance.com ↗ |
Trials 63 · started per year
today
1
1
3
2
1
1
1
1
2
6
6
2
11
5
4
9
3
3
2007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 012 trials | ||||||
| Phase 0 | NCT07700121 | Oct 2026 → Oct 2028 expected | metastatic melanoma | Abramson Cancer Center at Penn Medicine | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT05649618 | Dec 2022 → Mar 2024 | cancer | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT05333588 | Feb 2022 → Feb 2024 | adult glioblastoma | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
| Phase 0 | NCT05087745 | Dec 2021 → Dec 2024 | neoplasm | Shanghai Juncell Therapeutics | Unknown | No outcome recorded |
| Phase 0 | NCT05142475 | Nov 2021 → Dec 2026 expected | breast cancer | Shanghai Juncell Therapeutics | Recruiting | No outcome recorded |
| Phase 0 | NCT05098197 | Sep 2021 → Sep 2026 overdue | immunotherapy induced hypophysitis, liver cancer | Shanghai Juncell Therapeutics | Recruiting | No outcome recorded |
| Phase 0 | NCT05098184 | Sep 2021 → Sep 2026 overdue | melanoma | Shanghai Juncell Therapeutics | Recruiting | No outcome recorded |
| Phase 0 | NCT04960072 | Jun 2021 → Dec 2025 overdue | digestive system neoplasm | Shanghai Juncell Therapeutics | Recruiting | No outcome recorded |
| Phase 0 | NCT04919616 | Jun 2021 → Jun 2023 | non-small cell lung carcinoma | Shanghai OriginCell Therapeutics Co., Ltd. | Unknown | No outcome recorded |
| Phase 0 | NCT04943913 | May 2021 → Dec 2026 expected | glioma | Shanghai Juncell Therapeutics | Recruiting | No outcome recorded |
| Phase 0 | NCT04967833 | Apr 2021 → Dec 2025 overdue | cancer | Shanghai Juncell Therapeutics | Recruiting | No outcome recorded |
| Phase 0 | NCT03526185 | Feb 2018 → Dec 2020 | metastatic melanoma | Yale University | Terminated | No outcome recorded Stop: Business |
| Phase 113 trials | ||||||
| Phase 1 | NCT06047977 | Jun 2025 → Sep 2029 expected | lymphoid hemopathy | H. Lee Moffitt Cancer Center and Research Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT06190249 | Dec 2024 → Jan 2028 | melanoma | James Isaacs, MD | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT06566092 | Mar 2024 → Jul 2026 overdue | Ewing sarcoma, central nervous system cancer, melanoma, rhabdomyosarcoma | Iovance Biotherapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06107894 | Jan 2024 → Sep 2025 | breast cancer, lung cancer | NeogenTC | Unknown | No outcome recorded |
| Phase 1 | NCT05768347 | Aug 2023 → Oct 2025 overdue | non-invasive bladder urothelial carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05681780 | Mar 2023 → Jun 2027 expected | non-small cell lung carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT05640193 | Nov 2022 → Nov 2027 expected | metastatic melanoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05607095 | Nov 2022 → May 2027 expected | metastatic melanoma, uveal melanoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05176470 | Jul 2022 → Jul 2023 overdue | cutaneous melanoma | Richard Wu | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04766320 | Jan 2021 → Dec 2022 | female reproductive organ cancer | Shanghai 10th People's Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT04443296 | Oct 2019 → Dec 2021 | cervical carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 1 | NCT01462903 | Sep 2011 → Nov 2014 | breast carcinoma, hepatocellular carcinoma, nasopharyngeal carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 1 | NCT00937300 | Jun 2009 → Jun 2011 | head and neck cancer, squamous cell carcinoma | Inge Marie Svane | Withdrawn | No outcome recorded |
| Phase 1/212 trials | ||||||
| Phase 1/2 | NCT06640582 | Oct 2024 → Sep 2026 overdue | glioblastoma, meningioma, metastatic malignant neoplasm in the brain, primary brain neoplasm | Essen Biotech | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06530303 | Sep 2024 → Sep 2026 overdue | colon carcinoma, rectal cancer | Essen Biotech | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06532799 | Sep 2024 → Dec 2025 overdue | esophageal cancer, gastric adenocarcinoma | Essen Biotech | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06532812 | Aug 2024 → Dec 2025 overdue | triple-negative breast carcinoma | Essen Biotech | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06538012 | Aug 2024 → Sep 2026 overdue | non-small cell lung carcinoma | Essen Biotech | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04611126 | Apr 2021 → Mar 2024 | fallopian tube cancer, ovarian cancer, peritoneal carcinoma | Inge Marie Svane | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT04538313 | Aug 2020 → Oct 2022 | hepatocellular carcinoma | CAR-T (Shanghai) Cell Biotechnology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04426669 | May 2020 → May 2025 | colorectal cancer, esophageal cancer, gallbladder cancer, gastric cancer +1 | Intima Bioscience, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04072263 | Aug 2018 → Aug 2021 | ovarian carcinoma | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT03638375 | Jul 2018 → Nov 2025 | drug allergy, poisoning | Leiden University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03374839 | Feb 2018 → Jan 2024 | melanoma | Nantes University Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT00937625 | Jun 2009 → Jan 2015 | melanoma | Inge Marie Svane | Completed | No outcome recorded |
| Phase 223 trials | ||||||
| Phase 2 | NCT07741877 | Oct 2026 → Sep 2033 expected | dedifferentiated liposarcoma, undifferentiated pleomorphic sarcoma | Iovance Biotherapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07288073 | Feb 2026 → Sep 2028 expected | cutaneous neuroendocrine carcinoma, skin squamous cell carcinoma | Karam Khaddour, MD, MS | Recruiting | No outcome recorded |
| Phase 2 | NCT07288203 | Nov 2025 → Dec 2027 expected | cutaneous melanoma | Iovance Biotherapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06455917 | Jan 2025 → Dec 2029 expected | non-small cell lung carcinoma | University Hospital, Basel, Switzerland | Recruiting | No outcome recorded |
| Phase 2 | NCT06481592 | Oct 2024 → May 2028 expected | endometrial cancer | Iovance Biotherapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06151847 | Dec 2023 → Jul 2025 | cutaneous melanoma, metastatic melanoma | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT04614103 | May 2021 → Dec 2030 expected | non-small cell lung carcinoma | Iovance Biotherapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT04111510 | Dec 2019 → Jan 2023 | triple-negative breast carcinoma | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT03935893 | Dec 2019 → Jun 2037 expected | colorectal cancer, cutaneous neuroendocrine carcinoma, gastric cancer, malignant pancreatic neoplasm +4 | Udai Kammula | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03935347 | Jun 2019 → May 2022 | bladder transitional cell carcinoma, renal pelvis urothelial carcinoma, ureter transitional cell carcinoma, urethra transitional cell carcinoma | Roswell Park Cancer Institute | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03645928 | May 2019 → Feb 2026 | head and neck squamous cell carcinoma, metastatic melanoma, non-small cell lung carcinoma | Iovance Biotherapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03801083 | Feb 2019 → Jan 2030 expected | cholangiocarcinoma | Udai Kammula | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03467516 | May 2018 → Jul 2027 expected | uveal melanoma | Udai Kammula | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03419559 | Feb 2018 → Dec 2021 | non-small cell lung carcinoma | Iovance Biotherapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT03108495 | Jun 2017 → Aug 2025 | cervical carcinoma | Iovance Biotherapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03083873 | Jan 2017 → Aug 2022 | head and neck squamous cell carcinoma | Iovance Biotherapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02375984 | Mar 2016 → Jun 2017 | metastatic melanoma | Saint John's Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT02360579 | Sep 2015 → Oct 2024 | metastatic melanoma | Iovance Biotherapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01883323 | Jun 2013 → Apr 2018 | metastatic melanoma | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT01369875 | Jun 2011 → Feb 2012 | metastatic melanoma, skin cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00863330 | Feb 2009 → Jul 2012 | cutaneous melanoma | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT00604136 | Jul 2008 → Dec 2019 | metastatic melanoma | Hadassah Medical Organization | Unknown | No outcome recorded |
| Phase 2 | NCT00513604 | Jun 2007 → Nov 2012 | melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05727904 | Mar 2023 → Mar 2028 expected | metastatic melanoma | Iovance Biotherapeutics, Inc. | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01701674 | Oct 2012 → Apr 2016 | metastatic melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05398640 | — | metastatic melanoma | Iovance Biotherapeutics, Inc. | Available | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT03158935 Background | Jul 2017 → Aug 2020 | melanoma, ovarian carcinoma | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 1/2 | NCT01369888 Background | May 2011 → May 2014 | metastatic melanoma, skin cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00006113 Background | Jun 1999 → May 2003 | cutaneous melanoma | University of Southern California | Terminated | No outcome recorded |
| Phase 3 | NCT06743126 Comparator | Jan 2025 → Jan 2028 expected | cutaneous melanoma | Immatics US, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 32
| Date | Issuer | Release |
|---|---|---|
| 2026-08-06 | Iovance Biotherapeutics, Inc. | Regulatory Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates iovance.com ↗
Fast Track Designation (FTD) Granted by the FDA for Lifileucel in Soft Tissue Sarcomas |
| 2026-06-03 | Iovance Biotherapeutics, Inc. | Regulatory Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia iovance.com ↗
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that the Therapeutic Goods Administration (TGA) of Australia granted approval with conditions of Amtagvi® (lifileucel), a tumor-derived autologous T cell immunotherapy, for previously treated advanced (metastatic or unresectable) melanoma. |
| 2026-05-07 | Iovance Biotherapeutics, Inc. | Results Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates iovance.com ↗
Iovance is well positioned through 2026 for long-term revenue growth, while advancing multiple ongoing and new clinical trials, including our registrational trial in advanced sarcomas now underway and encouraging initial data reported today for lifileucel in metastatic serous endometrial cancer. |
| 2026-02-24 | Iovance Biotherapeutics, Inc. | Regulatory Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates iovance.com ↗
U.S. FDA Fast Track Designation Granted for Lifileucel in Second-Line Advanced Non-Small Cell Lung Cancer |
| 2026-02-24 | Iovance Biotherapeutics, Inc. | Results Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas iovance.com ↗
Among the first six evaluable patients treated with lifileucel monotherapy, physician-assessed confirmed ORR by RECIST v1.1 was 50%. |
| 2026-02-05 | Iovance Biotherapeutics, Inc. | Results Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma iovance.com ↗
The physician-assessed confirmed objective response rate (ORR) was 44% (18/41) and the disease control rate was 73% (30/41). |
| 2025-11-06 | Iovance Biotherapeutics, Inc. | Results Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results iovance.com ↗
Best-in-Class Clinical Profile for Lifileucel in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) with Median Duration of Response Not Reached after 25+ Months Follow Up |
| 2025-11-03 | Iovance Biotherapeutics, Inc. | Results Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) iovance.com ↗
The objective response rate (ORR) was 25.6% by RECIST v1.1 following one-time treatment with lifileucel monotherapy in patients with advanced nonsquamous NSCLC. |
| 2025-08-18 | Iovance Biotherapeutics, Inc. | Regulatory Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma iovance.com ↗
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Amtagvi ® (lifileucel), a tumor-derived autologous T cell immunotherapy. |
| 2025-08-07 | Iovance Biotherapeutics, Inc. | Results Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 iovance.com ↗
The Journal of Clinical Oncology published the final five-year analysis from the Phase 2 C-144-01 clinical trial evaluating one-time lifileucel monotherapy, which represents unprecedented durability and duration of follow-up in previously treated advanced melanoma patients. |
| 2025-07-14 | Iovance Biotherapeutics, Inc. | Results Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma iovance.com ↗
Among 41 evaluable patients treated at four authorized treatment centers, the physician-assessed objective response rate (ORR) was 48.8% (20/41). |
| 2025-06-02 | Iovance Biotherapeutics, Inc. | Results The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma iovance.com ↗
One-time Amtagvi treatment demonstrated long-term benefit in heavily pretreated patients, including deep and durable responses, meaningful overall survival without further treatment, and no new or late-onset adverse events at a median follow-up of 57.8 months. |
| 2025-05-29 | Grit Biotechnology | Results 沙砾生物在ASCO 2025公布多项TIL细胞疗法临床进展 gritbio.com ↗
在11例复发性或转移性宫颈癌患者中展现出可控的安全性和良好的临床疗效。 |
| 2025-05-22 | Iovance Biotherapeutics, Inc. | Results Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting iovance.com ↗
today announced five-year results from the Phase 2 C-144-01 clinical trial evaluating the individualized T cell therapy Amtagvi ® (lifileucel). |
| 2025-05-01 | Intima Bioscience, Inc. | Results Data from First-in-Human Trial targeting CISH, a Novel Immune Checkpoint, in Patients with Metastatic Colorectal Cancer intimabioscience.com ↗
Ongoing and Durable Complete Response of Two Years Observed in Patient with Young Adult Colorectal Cancer Refractory to Multiple Lines of Chemotherapy and Immunotherapy |
| 2025-02-08 | Grit Biotechnology | Results 全球首款创新型肿瘤浸润淋巴细胞疗法在上海九院完成首例口腔癌患者细胞回输并达到完全缓解 gritbio.com ↗
由沙砾生物及上海九院合作研发及开展的创新型肿瘤浸润淋巴细胞疗法（TIL）GT201在临床研究中首例头颈癌病人药效评估达到完全缓解（“CR”），肿瘤病灶已完全消失，标志着我国在TIL细胞治疗实体肿瘤领域取得重大突破。 |
| 2024-11-07 | Iovance Biotherapeutics, Inc. | Regulatory Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024 iovance.com ↗
Marketing Authorization Applications Validated and Accepted for Review by European Regulatory Authorities for Potential Approval Starting with the UK in 1H2025 and EU and Canada in 2H2025 |
| 2024-06-28 | Iovance Biotherapeutics, Inc. | Regulatory Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma iovance.com ↗ |
| 2024-05-23 | Iovance Biotherapeutics, Inc. | Results Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting iovance.com ↗
Confirmed ORR was 65.2%, including 7 (30.4%) complete responses and 8 (34.8%) partial responses by RECIST v1.1. |
| 2024-03-04 | Iovance Biotherapeutics, Inc. | Regulatory Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer iovance.com ↗
today announced that the U.S. Food and Drug Administration (FDA) lifted a partial clinical hold placed on the registrational IOV-LUN-202 trial investigating LN-145 TIL cell therapy in non-small cell lung cancer (NSCLC). |
| 2024-02-16 | Iovance Biotherapeutics, Inc. | Regulatory Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma iovance.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has approved AMTAGVI™ (lifileucel) suspension for intravenous infusion. |
| 2023-12-27 | Iovance Biotherapeutics, Inc. | Regulatory Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer iovance.com ↗
The U.S. Food and Drug Administration (FDA) placed a clinical hold on the IOV-LUN-202 trial on December 22, 2023 , in response to a recently reported Grade 5 (fatal) serious adverse event potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen. |
| 2023-10-31 | Iovance Biotherapeutics, Inc. | Results Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting iovance.com ↗
One-time lifileucel TIL therapy demonstrated durable efficacy with a four-year OS rate of 22.2%. |
| 2023-10-16 | Iovance Biotherapeutics, Inc. | Results Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Advanced Mucosal Melanoma at the European Society for Medical Oncology (ESMO) Congress iovance.com ↗
The ORR assessed by an independent review committee (IRC) using RECIST v1.1 was 50% (95% CI: 21%–79%). |
| 2023-09-14 | Iovance Biotherapeutics, Inc. | Regulatory U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma iovance.com ↗ |
| 2023-07-10 | Iovance Biotherapeutics, Inc. | Regulatory Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer iovance.com ↗
Positive FDA Feedback Supports IOV-LUN-202 Trial Design for Accelerated Approval of TIL Therapy in Post-Anti-PD-1 Advanced Non-Small Cell Lung Cancer |
| 2023-05-26 | Iovance Biotherapeutics, Inc. | Regulatory Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma iovance.com ↗ |
| 2023-03-24 | Iovance Biotherapeutics, Inc. | Regulatory Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma iovance.com ↗
today announced it has completed its rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for lifileucel. |
| 2023-01-23 | Iovance Biotherapeutics, Inc. | Results Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates iovance.com ↗
Positive Clinical Data in Anti-PD-1 Naïve Metastatic Non-Small Cell Lung Cancer (NSCLC) |
| 2022-11-10 | Iovance Biotherapeutics, Inc. | Results Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting iovance.com ↗
The trial demonstrated a robust and clinically meaningful response rate and long-term durability following one-time treatment. |
| 2022-11-07 | Iovance Biotherapeutics, Inc. | Results Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting iovance.com ↗
The ORR assessed by an independent review committee (IRC) using RECIST v1.1 was 31% (95% CI: 24.1%-39.4%), with 8 complete responses (CRs) and 40 partial responses (PRs). |
| 2021-11-15 | Instil Bio | Results Instil Bio Announces Poster Presentations at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting instilbio.com ↗
Additionally, data were presented that showed CoStAR was transduced at high efficiency (greater than 40%) into primary ovarian cancer TILs and effector function of CoStAR-TIL was increased over untransduced TILs when cocultured with autologous tumor cells. |
All press releases naming this drug 38 releases
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 69 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tumor Infiltrating Lymphocytes | “adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TILs) and high-dose interleukin-2 (IL-2) administered to lymphodepleted patients with melanoma can...” PMID 23650429 ↗ May 201325“Accumulating evidence shows that tumor-infiltrating lymphocytes (TILs) selected for tumor recognition and greatly expanded in vitro are effective for treating cervical cancer patients.” NCT04443296 ↗ “Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion.” NCT04611126 ↗ “Two TIL (Tumor Infiltrating Lymphocytes) injections will be performed: at week 14 and at week 18.” NCT03374839 ↗ “Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells).” NCT00937300 ↗ “Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells).” NCT00937625 ↗ “TILs（Tumor Infiltrating Lymphocytes）” NCT04919616 ↗ “TILs（Tumor Infiltrating Lymphocytes）” NCT06455917 ↗ |
| Known as | AMTAGVI | “Administration of CD8 PET-guided infusion of lifileucel (AMTAGVI) on Day 0 following completion of the lymphodepleting chemotherapy regimen.” NCT07700121 ↗ |
| Known as | lifileucel | “tumor-infiltrating lymphocyte (TIL) cellular therapy, also called LN-145 or lifileucel” NCT07288073 ↗13“Infusion of lifileucel is then given” NCT05398640 ↗ |
| Known as | LN-144 | “Lifileucel (LN-144/LN-145) is an autologous Tumor Infiltrating Lymphocytes (TIL) cell therapy that utilizes a 22-day centralized GMP process.” NCT05607095 ↗2“Lifileucel (LN-144) is an autologous Tumor Infiltrating Lymphocytes (TIL) cell therapy that utilizes a 22-day centralized GMP process.” NCT05640193 ↗ |
| Known as | LN-144, TIL, autologous tumor-infiltrating lymphocytes | “LN-144, TIL, autologous tumor-infiltrating lymphocytes” NCT03645928 ↗ |
| Known as | LN-145 | “Lifileucel (LN-144/LN-145) is an autologous Tumor Infiltrating Lymphocytes (TIL) cell therapy that utilizes a 22-day centralized GMP process.” NCT05607095 ↗ |
| Known as | LN-145/LN-144 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06566092 ↗ |
| Known as | TIL | “adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TILs) and high-dose interleukin-2 (IL-2) administered to lymphodepleted patients with melanoma can...” PMID 23650429 ↗ May 20138“Biological: Tumor Infiltrating Lymphocytes (TIL) Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.” NCT04967833 ↗ “Tumor infiltrating lymphocytes (TIL) are white blood cells that have been taken from tumor tissue.” NCT01369875 ↗ “treatment with tumour infiltrating lymphocytes (TIL) and interferon-alpha (IFNa).” PMID 33234662 ↗ Nov 2020 “Biological: Tumor Infiltrating Lymphocytes (TIL)” NCT03467516 ↗ “Tumor Infiltrating Lymphocytes (TIL)” NCT04766320 ↗ “Tumor Infiltrating Lymphocytes (TIL)” NCT00863330 ↗ |
| Known as | TILs | “Accumulating evidence shows that tumor-infiltrating lymphocytes (TILs) selected for tumor recognition and greatly expanded in vitro are effective for treating cervical cancer patients.” NCT04443296 ↗7“Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with fludarabine and cyclophosphamide.” NCT04766320 ↗ “Tumor-infiltrating lymphocytes (TILs) therapy is an advanced form of adoptive cell therapy that harnesses the patient's immune cells to fight cancer.” NCT06532812 ↗ “TILs are expanded from tumor resections or biopsies, and after ex vivo stimulation, activation and extensive expansion, are reinfused to patients” NCT05649618 ↗ “autologous TILs, a type of white blood cell that recognizes tumor cells and enters them, thereby causing tumor cells to break down.” NCT03158935 ↗ “Tumor-infiltrating lymphocytes (TILs) therapy is an innovative form of adoptive cell therapy” NCT06538012 ↗ |
| Known as | Tumor infiltrating lymphocyte | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04538313 ↗ |
| Known as | Tumor Infiltrating Lymphocytes (TIL) | “Tumor Infiltrating Lymphocytes (TIL)” NCT01701674 ↗ |
| Action | Deplete | “causing tumor cells to break down” NCT03158935 ↗ |
| Modality | Cell therapy | “therapeutic tumor infiltrating lymphocytes” NCT00006113 ↗ |
| Route | Intravenous | “Patients receive an IV infusion of the treated cells” NCT00513604 ↗ |